Clinical Trials Directory
To join this study, you will go to Duke hospital for surgery. During surgery, doctors will place a small tube called a catheter to give you the study medicine and take a tiny piece of tissue for research. After surgery, you will stay in the hospital while the first medicine, called D2C7-IT, goes in for about three days. Then you will get another medicine called 2141-V11, which takes about seven hours. After the medicines are done, the tube will be removed, and you will be watched for six hours. About two weeks later, you will come back to start getting shots of 2141-V11 under your skin. You may keep getting these shots for up to a year, and even longer if you want. When you stop the shots, your doctor will decide what follow-up you need.
We are doing this study to collect information about how well dabrafenib plus trametinib works in patients who have unresectable (cannot be removed by surgery) or metastatic BRAF V600E mutation positive solid tumors.
We are doing this study to collect and store information and samples that will be used for future research studies about transplants.
We are doing this study to collect and store your medical information and specimens for use in future research studies to understand heart function and disease.
We are doing this study to find out how well an emotion regulation skills training program can help expecting mothers lower stress during pregnancy and improve their heart rate.
What happens in this study? - People will do a 30-minute interview by phone or Zoom - The interview will be recorded - No follow-up visits or interviews will happen after that
This study includes several steps and lasts about 208 days in total. It begins with a screening period that lasts 28 days. During this time, you will have a full physical exam, your medical history will be reviewed, and you will have routine lab tests, a heart test called an electrocardiogram, and a sensor placed to check your blood sugar levels. If you qualify and choose to join, you will be randomly assigned on the first dose day to receive either the study drug, called CNP-103, or a placebo, which does not contain any active medicine. The medicine or placebo will be given through a vein. The treatment period lasts 90 days, followed by another 90 days of follow-up. During this time, doctors will check how your body reacts to the medicine and how safe it is.
Everyone who shows interest and passes an early screening will be invited to join all three design group sessions. At the first session, the team will explain what the sessions are about, the benefits and risks, and ask people to give consent. They will also complete some short assessments. The total time for all three sessions will be about three hours, and the team will schedule them at times that work best for the doctors, patients, and caregivers taking part. All three sessions will be held online. In these sessions, doctors and patient or caregiver participants will help design and improve a new tool that supports medical decision making.